Francine Foss, MD, reviews optimal management of a highly functional patient presenting with de novo tumor-stage mycosis fungoides.
Upon completion of this activity, participants should be able to:
Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma
GADOLIN: Obinutuzumab + Bendamustine and Maintenance Obinutuzumab in Rituximab-Refractory Indolent NHL
CD19 CAR-T Cells Induce Durable Responses in Relapsed/Refractory CD19-Positive Lymphomas
Improved PFS With Addition of Idelalisib to Ofatumumab in Previously Treated CLL
Frontline Brentuximab Vedotin + R-CHOP Yields High Response Rate in DLBCL
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.